Trial
NCT06515418
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
BioAge Labs, Inc.
Collaborators
Eli Lilly and Company
Condition
Obesity
Intervention
Oral Azelaprag (BGE-105)
Why stopped
Dosing of both study drugs has been discontinued due to observation of liver transaminitis without clinically significant symptoms in some subjects receiving azelaprag. All participant visits have been completed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-13